AChR-specific immunosuppressive therapy of myasthenia gravis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Biochemical Pharmacology

• Publication date

  2015-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bcp.2015.07.011PMID 26215875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Myasthenia gravis

  2019cited by this paper
• Regulatory function of CD4+CD25++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-Dihydroxyvitamin D3 modulates the suppressor activity

  2015cited by this paper
• Significant Roles of Regulatory T Cells and Myeloid Derived Suppressor Cells in Hepatitis B Virus Persistent Infection and Hepatitis B Virus-Related HCCs

  2015cited by this paper
• Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis

  2015cited by this paper
• Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients

  2014cited by this paper
• Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches.

  2014cited by this paper
• Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-α.

  2014cited by this paper
• Treatment-Refractory Myasthenia Gravis

  2014cited by this paper
• Antigen-Specific Immunotherapeutic Vaccine for Experimental Autoimmune Myasthenia Gravis

  2014cited by this paper
• Is thymectomy in non-thymomatous myasthenia gravis of any benefit?

  2014cited by this paper
• Novel future therapeutic options in myasthenia gravis.

  2013cited by this paper
• Recent Advances in Genetic Predisposition of Myasthenia Gravis

  2013cited by this paper
• Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model.

  2013cited by this paper
• Implication of double‐stranded RNA signaling in the etiology of autoimmune myasthenia gravis

  2013cited by this paper
• Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future

  2012cited by this paper
• Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis.

  2012cited by this paper
• Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.

  2012cited by this paper
• Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

  2012cited by this paper
• Optimization of current and future therapy for autoimmune diseases

  2012cited by this paper
• End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease.

  2012cited by this paper
• Myasthenogenicity of the main immunogenic region

  2012cited by this paper
• Progress of treatment in myasthenia gravis

  2012cited by this paper
• Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors

  2012cited by this paper
• Complement-Fixing Anti-Type VII Collagen Antibodies Are Induced in Th1-Polarized Lymph Nodes of Epidermolysis Bullosa Acquisita-Susceptible Mice

  2011cited by this paper
• Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis

  2011cited by this paper
• Human FoxP3+ regulatory T cells in systemic autoimmune diseases.

  2011cited by this paper
• This information is current as Development of Long-Lived Plasma Cells Autoimmunity by Suppressing the Regulatory T Cells Control Humoral + Foxp 3

  2010cited by this paper
• The loop between β‐strands β2 and β3 and its interaction with the N‐terminal α‐helix is essential for biogenesis of α7 nicotinic receptors

  2010cited by this paper
• Specific immunotherapy of experimental myasthenia gravis by a novel mechanism

  2010cited by this paper
• The Role of Rituximab in the Treatment of Myasthenia Gravis

  2010cited by this paper
• Zero tolerance (to acetylcholine receptor) and ways to overcome it

  2010cited by this paper
• Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction

  2010cited by this paper
• Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis

  2010cited by this paper
• Antigen-specific immunotherapy of autoimmune and allergic diseases

  2010cited by this paper
• Towards an understanding of the adjuvant action of aluminium

  2009cited by this paper
• Antigenic Structure of the Human Muscle Nicotinic Acetylcholine Receptor Main Immunogenic Region

  2009cited by this paper
• Main Immunogenic Region Structure Promotes Binding of Conformation-Dependent Myasthenia Gravis Autoantibodies, Nicotinic Acetylcholine Receptor Conformation Maturation, and Agonist Sensitivity

  2009cited by this paper
• Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?

  2009cited by this paper
• Prednisolone Treatment Induces Tolerogenic Dendritic Cells and a Regulatory Milieu in Myasthenia Gravis Patients1

  2009cited by this paper
• Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals

  2009cited by this paper
• Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.

  2008cited by this paper
• Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis.

  2008cited by this paper
• Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone

  2008cited by this paper
• Myasthenia Gravis and the Tops and Bottoms of AChRs

  2008cited by this paper
• Ex Vivo Generated Regulatory T Cells Modulate Experimental Autoimmune Myasthenia Gravis1

  2008cited by this paper
• Review: Progress in the treatment of myasthenia gravis

  2008cited by this paper
• Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

  2007cited by this paper
• FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis.

  2007cited by this paper
• FcγRIIb controls bone marrow plasma cell persistence and apoptosis

  2007cited by this paper
• Myasthenia gravis: past, present, and future.

  2006cited by this paper
• Oral Tolerance: Therapeutic Implications for Autoimmune Diseases

  2006cited by this paper
• Mathematical modeling of humoral immune response suppression by passively administered antibodies in mice.

  2006cited by this paper
• Refined structure of the nicotinic acetylcholine receptor at 4A resolution.

  2005cited by this paper
• Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis.

  2005cited by this paper
• Circulating and thymic CD4+ CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment

  2005cited by this paper
• Clinical evaluation and management of myasthenia gravis

  2004cited by this paper
• The Epidemiology of Myasthenia Gravis

  2004cited by this paper
• Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment.

  2004cited by this paper
• Adjuvant-dependent modulation of T h 1 and T h 2 responses to immunization with b-amyloid

  2003cited by this paper
• Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.

  2003cited by this paper
• Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis.

  2003cited by this paper
• The Epidemiology of Myasthenia Gravis

  2003cited by this paper
• Immunotherapy in autoimmune neuromuscular disorders.

  2003cited by this paper
• Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases.

  2002cited by this paper
• Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

  2001influential reference
• Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors

  2001cited by this paper
• Rat models as tool to develop new immunotherapies

  2001cited by this paper
• Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis.

  2000cited by this paper
• Acetylcholine receptors and myasthenia

  2000cited by this paper
• Role of Tolerogen Conformation in Induction of Oral Tolerance in Experimental Autoimmune Myasthenia Gravis1

  2000cited by this paper
• Regulation of antibody responses via antibodies, complement, and Fc receptors.

  2000cited by this paper
• Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.

  1999cited by this paper
• Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis.

  1999cited by this paper
• Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.

  1999cited by this paper
• Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit.

  1999cited by this paper
• Anatomy of the antigenic structure of a large memberane autoantigen, the muscle‐type nicotinic acetylcholine receptor

  1998cited by this paper
• Molecular and Antigenic Structure of Nicotinic Acetylcholine Receptors

  1998cited by this paper
• Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals

  1998cited by this paper
• Expression of human–Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis (MG)

  1997cited by this paper
• Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis.

  1997cited by this paper
• Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases.

  1997cited by this paper
• Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.

  1997cited by this paper
• Functional diversity of helper T lymphocytes

  1996cited by this paper
• Induction of Autoimmune Diabetes by Oral Administration of Autoantigen

  1996cited by this paper
• Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting.

  1996cited by this paper
• Three-dimensional location of the main immunogenic region of the acetylcholine receptor.

  1995cited by this paper
• Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor.

  1995cited by this paper
• Myasthenia gravis.

  1994cited by this paper
• Oral administration of acetylcholine receptor: Effects on experimental myasthenia gravis

  1994cited by this paper
• Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor.

  1993cited by this paper
• Myasthenia gravis: recognition of a human autoantigen at the molecular level.

  1993cited by this paper
• Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor.

  1993cited by this paper
• Myasthenia gravis and myasthenic syndromes.

  1992cited by this paper
• Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide.

  1992cited by this paper
• Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis.

  1991cited by this paper
• Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis

  1990cited by this paper
• TE671 cells express an abundance of a partially mature acetylcholine receptor alpha subunit which has characteristics of an assembly intermediate.

  1990cited by this paper
• The Membrane Attack Complex of Complement at the Endplate in Myasthenia Gravis a

  1987cited by this paper
• Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.

  1987cited by this paper
• Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor.

  1987cited by this paper

• Association between serum uric acid levels and myasthenia gravis: A meta-analysis

  2025cites this paper
• Surgical Expert Consensus on Clinical Management of Advanced Thymoma and Thymic Carcinoma: A Beijing–Tianjin–Hebei Collaborative Initiative

  2025cites this paper
• Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients

  2022cites this paper
• Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities

  2022cites this paper
• Autoimmunity to acetylcholine receptor channels

  2022cites this paper
• The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review)

  2021cites this paper
• Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis

  2021cites this paper
• Clinical features and outcome of acquired myasthenia gravis in 94 dogs

  2021cites this paper
• Analysis of the expression changes of IL-17+ γδ T cells and Treg cells in bone marrow mesenchymal stem cells targeted therapy for allergic rhinitis.

  2021cites this paper
• Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics

  2020cites this paper
• Effects of Mitophagy on Regulatory T Cell Function in Patients With Myasthenia Gravis

  2020cites this paper
• The correlation of neutrophil-to-lymphocyte ratio with the presence and short-time curative effect of myasthenia gravis in children: a retrospectively study

  2020cites this paper
• Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management

  2020cites this paper
• Myasthenia Gravis

  2019cites this paper
• Structure-Based Approaches to Antigen-Specific Therapy of Myasthenia Gravis

  2019cites this paper
• Treatment of experimental autoimmune myasthenia gravis rats with FTY720 and its effect on Th1/Th2 cells.

  2018cites this paper
• The nicotinic acetylcholine receptor as a molecular machine for neuromuscular transmission

  2018cites this paper
• Intensive Care Management of the Neuromuscular Patient

  2018cites this paper
• Acetylcholine receptor–specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis

  2018cites this paper
• Advances in autoimmune myasthenia gravis management

  2018cites this paper
• Emerging Therapeutics for Myasthenia Gravis

  2018cites this paper
• Human adipose tissue-derived mesenchymal stem cells ameliorate experimental autoimmune myasthenia gravis by modifying the balance of Th 1 / Th 2 / Th 17 / Treg cell subsets

  2017cites this paper
• Mechanisms of Autoantibody-Induced Pathology

  2017influential citation
• Pemphigus

  2017cites this paper
• Irrelevance of anti‑nAChR cytoplasmic loop antibody in the degree of myasthenia gravis.

  2017cites this paper
• Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications

  2017cites this paper
• A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1–T146

  2017influential citation
• The correlation of neutrophil-to-lymphocyte ratio with the presence and activity of myasthenia gravis

  2017cites this paper
• Serum uric acid levels in patients with myasthenia gravis are inversely correlated with disability

  2016cites this paper
• Low serum albumin concentrations are associated with disease severity in patients with myasthenia gravis

  2016cites this paper
• Myasthenia gravis due to hydroxychloroquine.

  2015cites this paper